We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

AbCheck and Pierre Fabre Enter into Strategic Research Partnership

AbCheck and Pierre Fabre Enter into Strategic Research Partnership

AbCheck and Pierre Fabre Enter into Strategic Research Partnership

AbCheck and Pierre Fabre Enter into Strategic Research Partnership

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AbCheck and Pierre Fabre Enter into Strategic Research Partnership"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AbCheck s.r.o and Pierre Fabre Pharmaceuticals have announced that they have expanded their ongoing collaboration into a strategic research partnership in the field of human antibody discovery and optimization.

AbCheck is recognized for its expertise in human antibody discovery and optimization throughout the US and Europe. Pierre Fabre, the third largest French pharmaceutical company, has a long-standing commitment to oncology and immunology. The Pierre Fabre Immunology Centre (CIPF) in Saint-Julien-en-Genevois, France, is dedicated to the identification, development and manufacturing of therapeutic monoclonal antibodies in focused therapeutic areas.

Under the expanded agreement, AbCheck will use its proprietary human antibody discovery and optimization platform technologies, AbSieve and AbAccel, to deliver antibodies against two or more targets provided by Pierre Fabre per year over a period of three years. This period can be extended to up to five years. Pierre Fabre has secured full rights to all antibodies selected in exchange for discovery fees and milestone payments to AbCheck. Additional deal terms as well as financial details were not disclosed.

We are extremely pleased that our technology platform, performance and business attitude has encouraged Pierre Fabre to select AbCheck as its main provider for therapeutic antibodies,” said Dr. Volker Lang, Managing Director of AbCheck. “This validation once more proves our ability to efficiently address the needs of our partners, which is instrumental to AbCheck’s future development.

At Pierre Fabre Immunology Center, we are working on a wide range of new promising targets and are always looking to reinforce our capabilities through collaborations with world-class platforms. This strategic partnership with AbCheck will support and accelerate our antibody discovery, said Dr. Nathalie Corvaïa, Managing Director of the Pierre Fabre Immunology Center.

Pierre Fabre is deeply committed to bringing targeted therapies to patients that need them as quickly as possible. This partnership with AbCheck coupled with our internal capabilities provides us with a platform to achieve this objective, added Prof. Laurent Audoly, Head of R&D, Pierre Fabre Pharmaceuticals.